Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Non-Alcoholic Fatty Liver Disease Clinical Trial

— SAMARA  

Official title:

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06005012
• Other study ID #: NRC-2023-1
• Status: Recruiting
• Phase: Phase 2
• Start date: July 25, 2023
• Est. completion date: June 2025

Study information

• Verified date: September 2023
• Source: University of California, San Diego
• Contact: Egbert Madamba
• Phone: (858) 246-2227
• Email: emadamba[@]health.ucsd.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.

Description:

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25-30% of the global population and is projected to become the leading cause of liver transplantation in the United States by 2030. Development of efficient screening strategies for the identification and treatment of individuals who are at greatest risk for advanced disease in this population is an urgent and unmet medical need. Type 2 diabetes mellitus (T2DM) and obesity are critical risk factors for advanced NAFLD. In a prospective cross-sectional study of patients with type 2 diabetes, we screened 524 participants (50-80 years old) with type 2 diabetes mellitus for the presence of NAFLD and observed relative prevalences of 70% for steatosis and 15% for advanced fibrosis. The presence of obesity in this population further increased the odds of advanced fibrosis. These findings suggest that screening populations of individuals with obesity or T2DM may be an effective strategy for identifying high-risk patients with NAFLD. Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic), conditions that are considered major risk factors for advanced fibrosis in the NAFLD population. It is unclear, however, whether semaglutide is effective for treatment of fibrosis due to NAFLD in these populations. Here, the investigators propose to conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: June 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 79 Years

Eligibility

Inclusion criteria:

1. Adult, age = 40 and < 80 years

2. Participant must meet at least one of following sets of conditions:

1. BMI = 27 kg/m² OR

2. BMI = 25 kg/m² AND presence of i) pre-diabetes (HbA1C = 5.7) or ii) type 2 diabetes mellitus (T2DM), as defined by the American Diabetes Association (ADA) clinical practice recommendations.

The ADA definition of T2DM is applicable if one of the following criteria is met:

• Presence of diabetes symptoms (polyuria, polydipsia, polyphagia, increased fatigue, weight loss, blurred vision) and casual plasma glucose = 200 mg/dL (11.1 mmol/L)

• Fasting plasma glucose (FPG) = 126 mg/dl (7.0 mmol/L)

• Plasma glucose = 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT)68. If any of the above test results occur, testing should be repeated on a different day to confirm the diagnosis.

OR

• Hemoglobin A1C (HbA1C) = 6.5% 6?.

3. FAST score = 0.5 and VCTE = 8.0 kPa; FAST score threshold based on data from MAESTRO-NASH trial4²; VCTE cutpoint based on AASLD guidelines for identification of patients with significant fibrosis risk.

4. Participants without a VCTE assessment in their medical record may qualify for the study if they have a FIB-4 = 1.0, which is a cutpoint based on observations of patients with T2DM in Ajmera et al³°, and VCTE = 8.0 kPa.

5. The subject is fully informed and willing and able to perform all the procedures specified in the protocol and has signed a written informed consent to participate

Exclusion criteria:

1. Presence of regular and/or excessive use of alcohol, defined as > 30 g/day for males and > 20 g/day for females, for a period longer than 2 years at any time in the last 10 years

2. Evidence of cirrhosis or previously known cirrhosis, based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices

3. VCTE = 20 kPa

4. Platelet count = 140,000 per Ml

5. Albumin < 3.6 g/dL

6. INR > 1.35, unless on coumadin for another indication

7. Serum creatinine > 2.0 mg/dL

8. eGFR < 30 mL/min/1.73 m² as defined according to the CKDEPI creatinine equation7°

9. Use of other weight loss medications, including GLP1RA within the last 90 days

10. Greater than 10% weight loss in the prior six months

11. Known or suspected hypersensitivity to GLP1RA medications including semaglutide

12. History of bariatric surgery within the past 5 years or expected bariatric surgery

13. Evidence of other causes of chronic liver disease including:

1. Hepatitis B, as defined as presence of hepatitis B surface antigen (HBsAg).

2. Previous or current infection with Hepatitis C, as defined by presence of hepatitis C virus Ab in serum (anti-HCV Ab).

3. Autoimmune hepatitis, as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.

4. Autoimmune cholestatic liver disorders, as defined by elevation of alkaline phosphatase and anti- mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.

5. Wilson disease, as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease deficiency, as defined by alpha-1-antitrypsin phenotype and liver histology consistent with alpha-1-antitrypsin deficiency.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Fatty Liver
• Fibrosis
• Fibrosis, Liver
• Liver Cirrhosis
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus in Obese

Intervention

Drug:
• Semaglutide
Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
• Placebo
Placebo

Locations

Country	Name	City	State
United States	University of California, San Diego	La Jolla	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in fibrosis due to NAFLD	Change in fibrosis due to Nonalcoholic fatty liver disease (NAFLD), as measured by change in FAST Score, which combines FibroScan results with aspartate aminotransferase (AST).	52 weeks
Secondary	Change in liver stiffness	Change in liver stiffness, as measured by change in Vibration-Controlled Transient Elastography	52 weeks
Secondary	Change in steatosis	Change in steatosis, as measure by a change in proton density fat fraction or controlled attenuation parameter	52 weeks
Secondary	Change in ALT	Change in ALT, as measured by a change in patients with ALT >= 30 U/L at baseline	52 weeks